NASDAQ$VERU
Veru Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Net revenues increased due to higher U.S. prescription sales of FC2.
Veru Inc. reported an increase in net revenues for the fiscal 2020 third quarter, driven by strong U.S. prescription sales of FC2 and a solid contribution from PREBOOST® / Roman Swipes®, along with lower operating expenses.
- Net revenues increased 6% to $10.3 million.
- FC2 U.S. prescription sales climbed 23% to $5.4 million.
- Operating loss narrowed to $1.4 million from $1.8 million.
- Net loss was $3.0 million, or $0.05 per share.
Headline financials
Revenue & EPS history
Veru · Revenue · Quarterly
$10.3M
Forward guidance
The company plans to submit the final Phase 3 protocol to the FDA in the fourth quarter of the current calendar year and anticipates commencing the global Phase 3 pivotal clinical study in the first quarter of calendar year 2021.
Tailwinds
- Received positive FDA input, agreement, and regulatory guidance regarding the design of the pivotal Phase 3 registration clinical trial for VERU-111.
- The proposed indication of metastatic castration and novel androgen receptor targeting agent resistant prostate cancer, which is prior to IV chemotherapy population, being acceptable.
- An open label, randomized, active control study using an alternative novel androgen receptor targeting agent as the active control is reasonable.
- A primary endpoint for the trial of radiographic progression-free survival.
- Patient enrollment of the Phase 2 trial is nearing completion and we are already observing some significant PSA declines.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2020
+1.5%
Avg return
Earnings day
+8.3%
Avg return
5 days after
+9.6%
Avg return
30 days after
45%
30 / 66 earnings
Positive
+83.7%
Q4 2020
Best reaction
-23.5%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +1.8% | -6.7% | +33.8% | |
| Q1 2026 | -0.4% | -0.9% | +3.5% | |
| Q4 2025 | -8.4% | -6.1% | +10.2% | |
| Q3 2025 | -12.0% | +0.0% | -0.8% | |
| Q2 2025 | +4.1% | +4.0% | +24.0% | |
| Q1 2025 | -4.5% | +0.0% | -12.7% | |
| Q4 2024 | -1.3% | -9.7% | +2.8% | |
| Q3 2024 | +7.1% | +6.5% | +10.4% | |
| Q4 2023 | +3.5% | +11.8% | -4.7% | |
| Q2 2024 | -16.0% | -18.4% | -43.6% | |
| Q1 2024 | -13.7% | -13.6% | +47.7% | |
| Q3 2023 | +5.6% | +3.7% | -4.6% | |
| Q2 2023 | -23.5% | -27.5% | -12.1% | |
| Q1 2023 | -19.1% | -21.8% | -57.5% | |
| Q4 2022 | +2.9% | -0.5% | -1.3% | |
| Q3 2022 | +62.1% | +89.0% | +32.3% | |
| Q2 2022 | +59.3% | +91.2% | +60.8% | |
| Q1 2022 | +9.4% | +7.4% | -8.8% | |
| Q4 2021 | -12.3% | -8.1% | -14.8% | |
| Q3 2021 | +8.8% | -2.0% | +31.3% | |
| Q2 2021 | -3.2% | +3.7% | +18.7% | |
| Q1 2021 | -2.3% | +7.8% | -22.3% | |
| Q4 2020 | +83.7% | +198.5% | +193.8% | |
| Q3 2020 | -11.6% | -10.9% | -9.9% | |
| Q2 2020 | +13.9% | +10.5% | -5.4% | |
| Q1 2020 | +0.9% | -0.9% | -29.8% | |
| Q4 2019 | -1.6% | +17.1% | +64.5% | |
| Q3 2019 | -14.0% | -11.0% | -16.2% | |
| Q2 2019 | -4.8% | -1.8% | +20.8% | |
| Q1 2019 | -8.1% | -10.7% | +0.0% | |
| Q4 2018 | -4.9% | +0.7% | -1.4% | |
| Q3 2018 | +1.0% | +1.0% | -13.6% | |
| Q2 2018 | -1.2% | +6.6% | +18.7% | |
| Q1 2018 | +0.8% | +2.3% | +50.4% | |
| Q4 2017 | +28.9% | +29.8% | +10.5% | |
| Q3 2017 | -11.3% | -4.0% | +2.0% | |
| Q2 2017 | -1.0% | -2.9% | +17.6% | |
| Q1 2017 | +1.9% | +3.8% | -1.9% | |
| Q4 2016 | -6.2% | -8.8% | -10.6% | |
| Q3 2016 | -2.3% | +1.6% | +2.3% | |
| Q2 2016 | -12.3% | — | — | |
| Q1 2016 | +10.2% | — | — | |
| Q4 2015 | +0.6% | — | — | |
| Q3 2015 | +9.9% | — | — | |
| Q2 2015 | -8.1% | — | — | |
| Q1 2015 | +2.9% | — | — | |
| Q4 2014 | -8.5% | — | — | |
| Q3 2014 | -5.8% | — | — | |
| Q2 2014 | -3.7% | — | — | |
| Q1 2014 | -4.1% | — | — | |
| Q4 2013 | +3.4% | — | — | |
| Q3 2013 | -3.3% | — | — | |
| Q2 2013 | +5.8% | — | — | |
| Q1 2013 | -4.2% | — | — | |
| Q4 2012 | -0.7% | — | — | |
| Q3 2012 | +4.7% | — | — | |
| Q2 2012 | -9.2% | — | — | |
| Q1 2011 | +1.5% | — | — | |
| Q1 2012 | +4.7% | — | — | |
| Q4 2009 | +5.5% | — | — | |
| Q4 2011 | +5.5% | — | — | |
| Q2 2011 | +5.5% | — | — | |
| Q4 2010 | -5.4% | — | — | |
| Q3 2010 | -5.4% | — | — | |
| Q3 2011 | -5.4% | — | — | |
| Q2 2010 | +0.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro